Changes in Serum Calprotectin and Their Clinical Correlates in Axial Spondyloarthritis Patients Undergoing Pulmonary Rehabilitation
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Giresun, Turquía (Türkiye), 28200
- Giresun University Faculty of Medicine
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Classification as axial spondyloarthritis according to the 2009 ASAS (Assessment of SpondyloArthritis International Society) criteria
- Age between 25 and 65 years
- Both male and female patients
- Ability to perform pulmonary function tests (PFTs) with full cooperation
Exclusion Criteria:
- Change in antirheumatic medication or dosage within the last 3 months
- Engagement in regular physical activity within the last 3 months
- History of unstable angina pectoris, cardiac arrhythmias, or myocardial infarction within the last 3 months
- Presence of any orthopedic, neurological, or mental disorder that could affect exercise performance
- History of pulmonary disease (asthma, COPD, atelectasis, etc.)
- Active malignancy and/or history of malignancy within the last 5 years
- History of syncope or exercise-induced arrhythmia
- Current pregnancy or planning pregnancy in the near future
- History of major surgery within the last 6 months
- Use of assistive devices for ambulation or presence of orthopedic joint prosthesis
- Patients with total spinal ankylosis
- Presence of a known additional rheumatologic disease
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in serum calprotectin levels before and after pulmonary rehabilitation.
Periodo de tiempo: Baseline and 4 weeks
|
The primary objective of this study was to evaluate the changes in serum calprotectin levels in patients with axial spondyloarthritis (axSpA) enrolled in a pulmonary rehabilitation program.
|
Baseline and 4 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in C-reactive protein [CRP] before and after pulmonary rehabilitation.
Periodo de tiempo: Baseline and 4 weeks
|
Measured via standard blood serum analysis in milligrams per liter (mg/L) from baseline to 4 weeks post-pulmonary rehabilitation.
|
Baseline and 4 weeks
|
|
Change in Erythrocyte Sedimentation Rate (ESR)
Periodo de tiempo: Baseline and 4 weeks
|
Measured in millimeters per hour (mm/hr) from baseline to 4 weeks post-pulmonary rehabilitation.
|
Baseline and 4 weeks
|
|
Change in Systemic Inflammation Response Index (SIRI)
Periodo de tiempo: Baseline and 4 weeks
|
Calculated from peripheral blood counts using the formula: SIRI = (Neutrophil count × Monocyte count) / Lymphocyte count.
Assessed as a unitless ratio to evaluate systemic inflammatory status from baseline to 4 weeks post-pulmonary rehabilitation.
|
Baseline and 4 weeks
|
|
Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
Periodo de tiempo: Baseline and 4 weeks
|
Assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Total score ranges from 0 to 10, where 0 indicates no disease activity and 10 indicates severe disease activity.
Higher scores represent worse outcomes.
|
Baseline and 4 weeks
|
|
Change in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Periodo de tiempo: Baseline and 4 weeks
|
Assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI) to evaluate functional limitations.
The BASFI consists of 10 items assessing daily physical activities.
Total score ranges from 0 to 10, where 0 represents easy/no functional impairment and 10 represents impossible/severe functional impairment.
Higher scores indicate worse functional limitations.
|
Baseline and 4 weeks
|
|
Change in Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP)
Periodo de tiempo: Baseline and 4 weeks
|
Assessed using the Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP), a composite index combining patient-reported assessments and serum C-reactive protein (CRP) levels.
Scores are categorized as: < 1.3 indicates inactive disease, 1.3 to 2.0 indicates moderate disease activity, 2.1 to 3.5 indicates high disease activity, and > 3.5 indicates very high disease activity.
Higher scores represent worse disease activity.
|
Baseline and 4 weeks
|
|
Change in St. George's Respiratory Questionnaire (SGRQ) Total Score
Periodo de tiempo: Baseline and 4 weeks
|
Assessed using the St. George's Respiratory Questionnaire (SGRQ) to measure health-related quality of life.
The questionnaire consists of 50 items across three domains: symptoms, activity, and impacts.
Total scores range from 0 to 100, where 0 indicates no impairment and 100 indicates maximum impairment.
Higher scores indicate worse health status and greater limitation.
|
Baseline and 4 weeks
|
|
Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Periodo de tiempo: Baseline and 4 weeks
|
Assessed using the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) to evaluate enthesitis across 13 anatomical locations bilaterally and at the 5th lumbar spinous process.
Tenderness is scored dichotomously (0 = absent, 1 = present).
Total score ranges from 0 to 13.
Higher scores indicate worse outcomes (more tender enthesis sites and greater disease activity).
|
Baseline and 4 weeks
|
|
Change in Nottingham Health Profile (NHP) Total Score
Periodo de tiempo: Baseline and 4 weeks
|
Assessed using the Nottingham Health Profile (NHP) to evaluate perceived emotional, social, and physical health problems across 38 items.
Each subscale score and the combined total score range from 0 to 100.
Higher scores indicate worse outcomes (greater perceived health problems and poorer quality of life).
|
Baseline and 4 weeks
|
|
Change in Systemic Immune-Inflammation Index (SII)
Periodo de tiempo: Baseline and 4 weeks
|
Calculated from peripheral blood counts using the formula: SII = (Platelet count × Neutrophil count) / Lymphocyte count.
Assessed as a unitless ratio from baseline to 4 weeks post-pulmonary rehabilitation.
|
Baseline and 4 weeks
|
|
Change in Neutrophil-to-Lymphocyte Ratio (NLR)
Periodo de tiempo: Baseline and 4 weeks
|
Calculated as the ratio of absolute neutrophil count to absolute lymphocyte count from baseline to 4 weeks post-pulmonary rehabilitation.
|
Baseline and 4 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Zerrin KASAP, Giresun University
- Investigador principal: Asude cevher ELMAS TELLİ, Giresun University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
Otros números de identificación del estudio
- Changes in Serum Calprotectin
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .